The Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded an indefinite delivery contract to Glaxosmithkline, LLC, a foreign-owned pharmaceutical company, to provide a range of pharmaceutical products and services under the Pandemic Influenza Preparedness and Response 2016-2021 program. The $2.11 billion multiple award contract has no set-aside designation and supports government efforts for disease prevention, immunization, drug stockpiling, and developing medical countermeasures like vaccines and antivirals. Task orders issued under this IDIQ contract include the delivery of influenza vaccine adjuvants, manufacturing of influenza vaccine antigens, storage and stability testing of vaccine stockpiles, and clinical studies for an H7N9 influenza vaccine. Glaxosmithkline will perform the contracted work at its facilities in Research Triangle Park, North Carolina. This contract and associated task orders aim to bolster the government's preparedness and response capabilities for pandemic influenza and other public health emergencies.
Glaxosmithkline has extensive experience providing pharmaceutical products and services to federal agencies, including the Departments of Defense, Veterans Affairs, Health and Human Services, and others, through both contracts and grants. The company has supplied a variety of vaccines, antiviral medications, and other medical countermeasures to support disease prevention efforts, immunization programs, correctional healthcare, and strategic national stockpiling initiatives. This IDIQ contract with ASPR allows the government to acquire these types of critical pharmaceutical goods and services on an as-needed basis to meet evolving public health preparedness requirements.
Generated 9/7/24, 10:53 AM